Estrogen biosynthesis (ovary)

"Estrogen production by ovary" refers to the physiological process whereby the ovaries synthesize estrogens—primarily estradiol—through a coordinated sequence involving both theca and granulosa cells. Theca cells convert cholesterol into androstenedione under luteinizing hormone stimulation; androstenedione then diffuses into granulosa cells where it is converted into estrone or estradiol via aromatase under follicle-stimulating hormone control. This multi-step pathway is essential for normal female reproductive function, menstrual cycle regulation, development of secondary sexual characteristics, neuroprotection, cardiovascular health, and bone maintenance. Disruption or dysregulation can contribute to diseases such as PCOS or hormone-dependent cancers. However, "estrogen production by ovary" itself is not a discrete molecular target like an enzyme or receptor; rather it describes a complex biological pathway involving multiple proteins—including aromatase—as potential therapeutic targets[1][2]. The entry "Estrogen production by ovary" does not correspond to a single molecule/receptor, but instead describes an entire biosynthetic process involving multiple enzymes (notably aromatase), cell types (theca/granulosa), hormones (FSH/LH), and regulatory mechanisms. For structured data purposes: *This should be flagged as incorrect for use as a canonical therapeutic target name.* Instead, specific components such as "Aromatase" (*CYP19A1*) should be used when referring to druggable targets within this pathway[1][2].

Other names

Ovarian estrogen productionOvarian estrogen synthesisEstrogen synthesis (ovary)

Drugs targeting this process typically: - Inhibit aromatase to block conversion of androge ns to estrogens in granulosa cells[1][2] - Suppress gonadotropin release to reduce ovarian stimulation